Oppenheimer Asset Management Inc. has increased its holdings in
West Pharmaceutical Services, Inc.(WST) by 1,951 shares. Despite slightly
underperforming in terms of stock compared to its competitors on certain days, many wonder if West holds
attractive growth drivers. Having presented at Bank of America's Global Healthcare Conference, West has readjusted its
full-year sales and
profit forecast due to subdued demand. Even with these changes, some experts question: is it time for everyone to consider buying WST's stocks? Multiple
financial management firms have increased their positions in WST, including
Victory Capital Management Inc. and
Vest Financial LLC. However, it's worth noting that A
chmea Investment Management B.V, and
Principal Financial Group Inc. have sold their WST shares. Despite this, analysts believe WST to be the leading
dividend aristocrat stock. In terms of
financial results, Q2 2024 earnings and revenues missed estimates, but Q1 earnings beat predictions, although with weak HVP sales. Questions arise for WST's Q2 2024
earnings report while the company delivers lukewarm forecasts due to lower demand. Their participation in upcoming investor conferences alongside a series of top-tier statements insinuates a positive outlook for their ongoing performance.
West Pharmaceutical Services WST News Analytics from Thu, 12 Oct 2017 07:00:00 GMT to Sun, 15 Sep 2024 15:19:06 GMT -
Rating 4
- Innovation 2
- Information 7
- Rumor -2
